Patients with metastatic melanoma have renewed hope in their fight against the most lethal form of skin cancer thanks to the FDA’s approval of a new treatment, Yervoy.

It marks the first major advancement in decades against a disease that affects more than 68,000 Americans each year.  In a recent clinical trial led by former Damon Runyon-Lilly Clinical Investigator Jedd. D. Wolchok, MD, PhD, nearly 50% of patients who received Yerboy survived for at least one year, compared to 25% of those who received other treatments.

Long before Yervoy got its brand name, Jedd was playing a key role in its development.

> Read the whole post: FDA Approves First Effective Melanoma Treatment in Decades